TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A Fading Hope?

被引：2

作者：

Perol, Maurice ^{[1
]}

机构：

[1] Leon Berard Canc Ctr, Dept Med Oncol, Lyon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 24期

关键词：

DATOPOTAMAB DERUXTECAN; SACITUZUMAB GOVITECAN; PHASE-III; PEMBROLIZUMAB;

D O I：

10.1200/JCO.24.01043

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：5

共 20 条

[1]

Ahn M., 2023, Ann Oncol, V34, pS1661

[2] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [J].

Bardia, A. ;

Messersmith, W. A. ;

Kio, E. A. ;

Berlin, J. D. ;

Vahdat, L. ;

Masters, G. A. ;

Moroose, R. ;

Santin, A. D. ;

Kalinsky, K. ;

Picozzi, V ;

O'Shaughnessy, J. ;

Gray, J. E. ;

Komiya, T. ;

Lang, J. M. ;

Chang, J. C. ;

Starodub, A. ;

Goldenberg, D. M. ;

Sharkey, R. M. ;

Maliakal, P. ;

Hong, Q. ;

Wegener, W. A. ;

Goswami, T. ;

Ocean, A. J. .

ANNALS OF ONCOLOGY, 2021, 32 (06) :746-756

[3] SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer [J].

Borghaei, H. ;

de Marinis, F. ;

Dumoulin, D. ;

Reynolds, C. ;

Theelen, W. S. M. E. ;

Percent, I. ;

Calderon, V. Gutierrez ;

Johnson, M. L. ;

Madroszyk-Flandin, A. ;

Garon, E. B. ;

He, K. ;

Planchard, D. ;

Reck, M. ;

Popat, S. ;

Herbst, R. S. ;

Leal, T. A. ;

Shazer, R. L. ;

Yan, X. ;

Harrigan, R. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2024, 35 (01) :66-76

[4]

Cho BC, 2023, J THORAC ONCOL, V18, pS54

[5] Antibody-drug conjugates come of age in oncology [J].

Dumontet, Charles ;

Reichert, Janice M. M. ;

Senter, Peter D. D. ;

Lambert, John M. M. ;

Beck, Alain .

NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (08) :641-661

[6] Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study [J].

Garassino, Marina C. ;

Gadgeel, Shirish ;

Speranza, Giovanna ;

Felip, Enriqueta ;

Esteban, Emilio ;

Domine, Manuel ;

Hochmair, Maximilian J. ;

Powell, Steven F. ;

Bischoff, Helge G. ;

Peled, Nir ;

Grossi, Francesco ;

Jennens, Ross R. ;

Reck, Martin ;

Hui, Rina ;

Garon, Edward B. ;

Kurata, Takayasu ;

Gray, Jhanelle E. ;

Schwarzenberger, Paul ;

Jensen, Erin ;

Pietanza, M. Catherine ;

Rodriguez-Abreu, Delvys .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) :1992-+

[7] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [J].

Garon, Edward B. ;

Ciuleanu, Tudor-Eliade ;

Arrieta, Oscar ;

Prabhash, Kumar ;

Syrigos, Konstantinos N. ;

Goksel, Tuncay ;

Park, Keunchil ;

Gorbunova, Vera ;

Dario Kowalyszyn, Ruben ;

Pikiel, Joanna ;

Czyzewicz, Grzegorz ;

Orlov, Sergey V. ;

Lewanski, Conrad R. ;

Thomas, Michael ;

Bidoli, Paolo ;

Dakhil, Shaker ;

Gans, Steven ;

Kim, Joo-Hang ;

Grigorescu, Alexandru ;

Karaseva, Nina ;

Reck, Martin ;

Cappuzzo, Federico ;

Alexandris, Ekaterine ;

Sashegyi, Andreas ;

Yurasov, Sergey ;

Perol, Maurice .

LANCET, 2014, 384 (9944) :665-673

[8] Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan [J].

Goldenberg, David M. ;

Sharkey, Robert M. .

MABS, 2019, 11 (06) :987-995

[9]

Goto Y, 2023, J CLIN ONCOL, V41

[10] Targeting Trop-2 as a Cancer Driver [J].

Guerra, Emanuela ;

Trerotola, Marco ;

Alberti, Saverio .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (29) :4688-+

← 1 2 →